Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

PURPOSE: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting the cell-surface antigen cMET....

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Payal D., Huang, Alexander C., Xu, Xiaowei, Orlowski, Robert, Amaravadi, Ravi K., Schuchter, Lynn M., Zhang, Paul, Tchou, Julia, Matlawski, Tina, Cervini, Amanda, Shea, Joanne, Gilmore, Joan, Lledo, Lester, Dengel, Karen, Marshall, Amy, Wherry, E. John, Linette, Gerald P., Brennan, Andrea, Gonzalez, Vanessa, Kulikovskaya, Irina, Lacey, Simon F., Plesa, Gabriela, June, Carl H., Vonderheide, Robert H., Mitchell, Tara C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167933/
https://www.ncbi.nlm.nih.gov/pubmed/37377890
http://dx.doi.org/10.1158/2767-9764.CRC-22-0486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167933/
https://www.ncbi.nlm.nih.gov/pubmed/37377890
http://dx.doi.org/10.1158/2767-9764.CRC-22-0486

Ejemplares similares